Dr. Hemalatha Ramachandran

Director - Digital Health Operations at iCliniq - The Virtual Hospital

[Dr. Hemalatha Ramachandran @hemrams]

@MarioBalsaMD Excellent review, Doctor. BRAF-fled perfectly captures the adaptive challenge of MAPK reactivation and phenotype switching. Pinpointing these specific resistance mechanisms is exactly how we build smarter sequencing. Thank you for making complex oncology so sharp and accessible.

[Dr. Hemalatha Ramachandran @hemrams]

@DrBarbiOnc Vital 15-year SOFT/TEXT data highlights the power of precise, tailored oncology, balancing treatment intensity with quality of life, say experts. True patient-centric care involves sitting with patients to navigate severe side effects for high-risk cases.

[Dr. Hemalatha Ramachandran @hemrams]

@drshieldsmd @ASCO @ASCOPost @ConquerCancerFd @IUCancerCenter @SclcSMASHERS @LUNGevity @LaurenByersMD @FordePatrick @g_mountzios Huge congratulations, Doctor. An incredibly well-deserved honor to serve as the #ASCO26 discussant. Your dedication to the Small Cell SMASHERS shines through, and these novel strategies bring genuine hope and progress to patients and families worldwide.

[Dr. Hemalatha Ramachandran @hemrams]

@BLLPHD @NEJM Fantastic milestone, Doctor. Expanding dual CD19 + BCMA CAR T to clear anti-donor antibody barriers for kidney transplants is a monumental first. Achieving this with zero severe CRS or neurotoxicity is a massive victory for precision immunology and sensitized patients.

[Dr. Hemalatha Ramachandran @hemrams]

@Neuroscope_mp Incredible news, Doctor. The latest peer-reviewed data on Buntanetap truly feels like a monumental shift for neurodegenerative care. Targeting translational pathways to address the root causes of both diseases simultaneously is a brilliantly elegant approach.

[Dr. Hemalatha Ramachandran @hemrams]

@drsarahsam Superb #ASCO26 synthesis, Doctor. The LidERA data on adjuvant giredestrant and the REDUSE de-escalation for bone mets are absolute game-changers. Amazing to see real progress in both precision escalation and reducing toxicity, costs to dramatically improve patient care.

[Dr. Hemalatha Ramachandran @hemrams]

@Dr_ElvinaA Incredible overview, Doctor. These 15-year SOFT/TEXT data underscore how crucial Ovarian Function Suppression is for young, high-risk premenopausal patients. A powerful reminder that escalating treatment with Exemestane + OFS genuinely moves the needle on long-term survival

[Dr. Hemalatha Ramachandran @hemrams]

@youngkwangchae Stunning results for LORIN at #ASCO26! A 46.9% pCR and getting 75% of unresectable patients to surgery is a monumental shift for stage III ALK+ NSCLC. Neoadjuvant lorlatinib is paving a powerful new path forward. Thanks for sharing this breakthrough,

[Dr. Hemalatha Ramachandran @hemrams]

@drjohnhaiti Such practical anatomy. Linking the C5-C6 skin line to asymmetrical upper body pain provides a brilliant, reliable clinical roadmap. It makes physical exams much more precise for neck and low back issues. Thanks for sharing this actionable diagnostic gem.

[Dr. Hemalatha Ramachandran @hemrams]

@JAMouabbi Fantastic insight from #ASCO26. For #ILC, where RECIST falls short, a 51% ctDNA clearance rate is a total game-changer. Using ctDNA dynamics as a literal compass to avoid flying blind is brilliant. This exploratory OS benefit (HR 0.39) is incredibly promising.

[Dr. Hemalatha Ramachandran @hemrams]

@youngkwangchae Incredible summary of OptiTROP-Lung05. A PFS HR of 0.35 in 1L NSCLC is an absolute home run. Excellent point on balancing that massive efficacy with the hematologic toxicity and global demographic data. Truly a monumental shift toward ADC+IO. Thanks for the breakdown

[Dr. Hemalatha Ramachandran @hemrams]

@ElisaAgostinett @OncoAlert Brilliant highlight from #ASCO26, Doctor. Transitioning from q4w to q12w denosumab is a massive win for patients-maintaining non-inferior efficacy while reducing ONJ and hypocalcemia risks is a huge relief. This is truly practice-changing news for oncology. Thanks for sharing.

[Dr. Hemalatha Ramachandran @hemrams]

@ArndtVogel @myESMO Incredible insight from CodeBreaK 300. Using ctDNA clearance as an early efficacy biomarker is a game-changer for KRAS G12C-mCRC tracking. This data proves we can evaluate treatment success much faster in a clinical setting. Thank you for sharing this crucial #ASCO26 update

[Dr. Hemalatha Ramachandran @hemrams]

@GIMedOnc Incredible 5-year update. A 49% reduction in recurrence for high-risk melanoma shows the immense power of individualized neoantigen therapy. Thank you for this brilliant breakdown-personalized mRNA vaccines are completely reshaping the future of oncology

[Dr. Hemalatha Ramachandran @hemrams]

@DrChoueiri @BradMcG04 @BraunMDPhD @AlbigesL @MikeSerzanMD @motzermd @DrRanaMcKay @VincentWenxinXu @DrYukselUrun @yekeduz_emre An incredible milestone for non-clear cell RCC. The 88% ORR in FH-deficient cases is historic. Thank you for sharing Dr. Feldman’s crucial #ASCO26 data-confirming CaboNivo as a first-line standard brings massive clarity and hope to patients with these rare subtypes

[Dr. Hemalatha Ramachandran @hemrams]

@Dr_ElvinaA Fantastic update. The rapid evolution of biomarker-driven therapies and next-gen ADCs like T-DXd is a monumental win for personalized oncology. Thank you for highlighting these precise options that offer so much hope and better outcomes for breast cancer patients

[Dr. Hemalatha Ramachandran @hemrams]

@BianchiniGP The REDUCE trial proves less can be more. Moving from a 4-week to a 12-week denosumab regimen maintains efficacy while boosting safety and cutting costs. Incredible win for patient-centric care and healthcare sustainability. Thanks for sharing.

[Dr. Hemalatha Ramachandran @hemrams]

@BalazsHalmosMD An incredible milestone, Doctor. Doubling overall survival through chemical biology is a monumental win against pancreatic cancer. It is wonderful that the RevMed EAP program will immediately bring this life-changing drug to patients in the Bronx.

[Dr. Hemalatha Ramachandran @hemrams]

@StephenVLiu @drshieldsmd Brilliant summary, Doctor. The Tarlatamab update truly raises the bar for SCLC treatment. Spotlighting ICANS awareness, especially regarding patients with brain metastases, is a vital clinical takeaway. Thank you for sharing this crucial #ASCO26 insight

[Dr. Hemalatha Ramachandran @hemrams]

@GIMedOnc A monumental milestone. Doubling OS to 13.2 months with a 0.40 HR in pancreatic cancer is historic. Turning the RAS target into a clinical reality while lowering toxicity changes everything. Brilliant breakdown of the RASolute 302 trial, Doctor.